These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
166 related articles for article (PubMed ID: 36235174)
1. Design, Synthesis and Biological Evaluation of Novel and Potent Protein Arginine Methyltransferases 5 Inhibitors for Cancer Therapy. Tang Y; Huang S; Chen X; Huang J; Lin Q; Huang L; Wang S; Zhu Q; Xu Y; Zou Y Molecules; 2022 Oct; 27(19):. PubMed ID: 36235174 [TBL] [Abstract][Full Text] [Related]
2. Discovery of 2-substituted-N-(3-(3,4-dihydroisoquinolin-2(1H)-yl)-2-hydroxypropyl)-1,2,3,4-tetrahydroisoquinoline-6-carboxamide as potent and selective protein arginine methyltransferases 5 inhibitors: Design, synthesis and biological evaluation. Shao J; Zhu K; Du D; Zhang Y; Tao H; Chen Z; Jiang H; Chen K; Luo C; Duan W Eur J Med Chem; 2019 Feb; 164():317-333. PubMed ID: 30605830 [TBL] [Abstract][Full Text] [Related]
3. Rational Design, synthesis and biological evaluation of novel triazole derivatives as potent and selective PRMT5 inhibitors with antitumor activity. Zhu K; Shao J; Tao H; Yan X; Luo C; Zhang H; Duan W J Comput Aided Mol Des; 2019 Aug; 33(8):775-785. PubMed ID: 31312965 [TBL] [Abstract][Full Text] [Related]
4. Arginine Methyltransferase 5 (PRMT5) Inhibitors with 3-(1H-benzo[d]imidazol- 2-yl)anilines Core Identified by Virtual Screening and Biological Evaluation. Zhang Y; Zhu K; Zhang J; Zhang JH; Song Z; Zhang X; Liu SK; Jiang CS Curr Pharm Des; 2023; 29(6):474-479. PubMed ID: 36790004 [TBL] [Abstract][Full Text] [Related]
5. Synthesis and biological evaluation of 1-phenyl-tetrahydro-β-carboline-based first dual PRMT5/EGFR inhibitors as potential anticancer agents. Zhang J; Liu X; Sa N; Zhang JH; Cai YS; Wang KM; Xu W; Jiang CS; Zhu KK Eur J Med Chem; 2024 Apr; 269():116341. PubMed ID: 38518523 [TBL] [Abstract][Full Text] [Related]
6. Structure-based discovery of a new series of nucleoside-derived ring-opening PRMT5 inhibitors. Chen Y; Wang Z; Zhang J; Shi Q; Yang H; Deng Y; Wang X; Liu T; Geng M; Xiong B; Huang X Eur J Med Chem; 2024 Mar; 267():116171. PubMed ID: 38301329 [TBL] [Abstract][Full Text] [Related]
7. Structure-Aided Design, Synthesis, and Biological Evaluation of Potent and Selective Non-Nucleoside Inhibitors Targeting Protein Arginine Methyltransferase 5. Rong D; Zhou K; Fang W; Yang H; Zhang Y; Shi Q; Huang Y; Li J; Dong H; Li L; Ding J; Huang X; Wang Y J Med Chem; 2022 Jun; 65(11):7854-7875. PubMed ID: 35612488 [TBL] [Abstract][Full Text] [Related]
8. Research Progress on Small-molecule Inhibitors of Protein Arginine Methyltransferase 5 (PRMT5) for Treating Cancer. Guo C; Wu L; Zheng X; Zhao L; Hou X; Wang Z; Han C Curr Top Med Chem; 2023; 23(21):2048-2074. PubMed ID: 37438905 [TBL] [Abstract][Full Text] [Related]
9. Discovery of Novel PRMT5 Inhibitors by Virtual Screening and Biological Evaluations. Tao H; Yan X; Zhu K; Zhang H Chem Pharm Bull (Tokyo); 2019; 67(4):382-388. PubMed ID: 30930442 [TBL] [Abstract][Full Text] [Related]
10. Discovery of new potent protein arginine methyltransferase 5 (PRMT5) inhibitors by assembly of key pharmacophores from known inhibitors. Zhu K; Song JL; Tao HR; Cheng ZQ; Jiang CS; Zhang H Bioorg Med Chem Lett; 2018 Dec; 28(23-24):3693-3699. PubMed ID: 30366617 [TBL] [Abstract][Full Text] [Related]
11. Discovery and optimization of selective inhibitors of protein arginine methyltransferase 5 by docking-based virtual screening. Ye Y; Zhang B; Mao R; Zhang C; Wang Y; Xing J; Liu YC; Luo X; Ding H; Yang Y; Zhou B; Jiang H; Chen K; Luo C; Zheng M Org Biomol Chem; 2017 May; 15(17):3648-3661. PubMed ID: 28397890 [TBL] [Abstract][Full Text] [Related]
12. Discovery of selective protein arginine methyltransferase 5 inhibitors and biological evaluations. Ji S; Ma S; Wang WJ; Huang SZ; Wang TQ; Xiang R; Hu YG; Chen Q; Li LL; Yang SY Chem Biol Drug Des; 2017 Apr; 89(4):585-598. PubMed ID: 27714957 [TBL] [Abstract][Full Text] [Related]
13. Discovery of novel PRMT5 inhibitors bearing a methylpiperazinyl moiety. Bai X; Zhai Z; Zhao X; Li R; Liang L; Jin Y; Yin Y Future Med Chem; 2022 Jul; 14(14):1071-1086. PubMed ID: 35748226 [No Abstract] [Full Text] [Related]
14. Medicinal chemistry strategies targeting PRMT5 for cancer therapy. Fu S; Zheng Q; Zhang D; Lin C; Ouyang L; Zhang J; Chen L Eur J Med Chem; 2022 Dec; 244():114842. PubMed ID: 36274274 [TBL] [Abstract][Full Text] [Related]
15. Identification of PRMT5 inhibitors with novel scaffold structures through virtual screening and biological evaluations. Zhang Q; Zhang L; Jin J; Fan Y; Wang X; Hu H; Ye X; Wang L; Cao C; Ye F J Mol Model; 2022 Jun; 28(7):184. PubMed ID: 35680707 [TBL] [Abstract][Full Text] [Related]
16. The Discovery of Two Novel Classes of 5,5-Bicyclic Nucleoside-Derived PRMT5 Inhibitors for the Treatment of Cancer. Quiroz RV; Reutershan MH; Schneider SE; Sloman D; Lacey BM; Swalm BM; Yeung CS; Gibeau C; Spellman DS; Rankic DA; Chen D; Witter D; Linn D; Munsell E; Feng G; Xu H; Hughes JME; Lim J; Saurí J; Geddes K; Wan M; Mansueto MS; Follmer NE; Fier PS; Siliphaivanh P; Daublain P; Palte RL; Hayes RP; Lee S; Kawamura S; Silverman S; Sanyal S; Henderson TJ; Ye Y; Gao Y; Nicholson B; Machacek MR J Med Chem; 2021 Apr; 64(7):3911-3939. PubMed ID: 33755451 [TBL] [Abstract][Full Text] [Related]
17. Novel Chemicals Derived from Tadalafil Exhibit PRMT5 Inhibition and Promising Activities against Breast Cancer. Yang Z; Xiao T; Li Z; Zhang J; Chen S Int J Mol Sci; 2022 Apr; 23(9):. PubMed ID: 35563196 [TBL] [Abstract][Full Text] [Related]
18. A patent review of PRMT5 inhibitors to treat cancer (2018 - present). Gao J; Yang J; Xue S; Ding H; Lin H; Luo C Expert Opin Ther Pat; 2023 Apr; 33(4):265-292. PubMed ID: 37072380 [TBL] [Abstract][Full Text] [Related]
19. Development of an AlphaLISA high throughput technique to screen for small molecule inhibitors targeting protein arginine methyltransferases. Prabhu L; Chen L; Wei H; Demir Ö; Safa A; Zeng L; Amaro RE; O'Neil BH; Zhang ZY; Lu T Mol Biosyst; 2017 Nov; 13(12):2509-2520. PubMed ID: 29099132 [TBL] [Abstract][Full Text] [Related]
20. Structure-activity relationship study of a series of nucleoside derivatives bearing sulfonamide scaffold as potent and selective PRMT5 inhibitors. Chen Y; Shi Q; Yang H; Li J; Zhou K; Zhang J; Wang Z; Shi H; Xiong B; Liu J; Huang X; Liu T Bioorg Chem; 2023 Jan; 130():106228. PubMed ID: 36356371 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]